Zyversa Therapeutics, Inc. has entered into a Sales Agreement with A.G.P/Alliance Global Partners, allowing the company to offer and sell shares of common stock totaling up to $1,397,396 in an at-the-market public offering. The Agent will receive a 3.00% commission from any sales made under this agreement. Zyversa may sell shares at its discretion, with no obligation on either party to proceed with any sales. The offering may be suspended or terminated by either party with proper notice and is subject to conditions.
The agreement includes indemnity provisions for the Agent against certain liabilities. Shares will be offered under the company's existing shelf registration statement and prospectus file. Proceeds from the sale of shares are intended for working capital and other general corporate purposes. Investors should read the Sales Agreement terms with consideration of the company's ongoing disclosures.